abiraterone-acetate and Substance-Withdrawal-Syndrome

Abiraterone acetate (AA) is an androgen receptor axis inhibitor, indicated together with prednisone, for metastatic castration-resistant prostate cancer. Withdrawal syndrome for classical antiandrogen treatments is well known, but not so known for AA. Abiraterone withdrawal syndrome (AWS) could be related to simultaneous prednisone discontinuation or to an androgenic effect of AA metabolites.. A case is described of a patient with long-term AWS without prednisone discontinuation. The clinical and prostate-specific antigen (PSA) response allowed an 8-month delay in docetaxel treatment.. Prednisone did not play a role in AWS in this case. The long-term response allowed a delay in future treatment.

Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Substance Withdrawal Syndrome; Treatment Outcome

Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Substance Withdrawal Syndrome

Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Disease Progression; Drug Administration Schedule; Humans; Kallikreins; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Substance Withdrawal Syndrome; Time Factors

Topics: Abiraterone Acetate; Aged; Androstadienes; Drug Resistance, Neoplasm; Humans; Male; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Substance Withdrawal Syndrome; Tomography, X-Ray Computed; Treatment Failure